-
Sen. Bernie Sanders’ broad statement on U.S. drug prices doesn’t paint the full picture. Studies we examined generally found that U.S. prices were 2 to 4 times those in other countries, not 10.
-
Doctors have no national standards on when to order urine tests to check whether adult ADHD patients are properly taking their medication. Some patients are subjected to much more frequent testing than others.
-
The Senate Health Policy Committee approved the bill, while the House Healthcare Regulation Subcommittee is slated to take up its version on Tuesday.
-
The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live.
-
The billionaire entrepreneur, Dallas Mavericks owner and "Shark Tank" star is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
-
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
-
Twitter has been a hotbed for the insulin access movement and activism surrounding other medical conditions - helping propel concern about the prices into policy. Can it continue to win with hashtags?
-
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
-
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for COVID. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
-
It’s understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our system’s reckless spending: They cover up a drug’s true price, much of which insurers pay, and that contributes to rising premiums.
-
Small pharmacies have long complained about benefit managers, which represent health insurers in negotiations with drug companies and pharmacies
-
The state, which continues to wait for FDA approval, expects to import drugs to treat asthma, COPD, diabetes, hepatitis C, HIV and AIDS, and mental health conditions.